Latest Metformin Stories
PARIS, Feb. 19, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union. (Logo:...
SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today the closing of a $20 million Series C financing to fund development of product candidates NewMet(TM) for Type 2 diabetes and Lovidia(TM), an over-the-counter weight loss product. The financing was led by GSM Fund LLC, a fund dedicated to this single investment and managed by Rick Barry, who has been elected to the Elcelyx Board of Directors. All previous investors also participated in the round, including...
NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be...
FORT LAUDERDALE, Fla., Feb. 7, 2013 /PRNewswire/ -- It's quite possible you may have someone in your family or know of someone who has a friend or loved one that has been diagnosed with Alzheimer's. According to an article in the March issue of Life Extension® Magazine, someone in America develops Alzheimer's every 68 seconds and that rate is projected to more than double by 2050, to one every 33 seconds. (Logo: http://photos.prnewswire.com/prnh/20120223/FL58611LOGO-b ) But just...
CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire/ -- Crown Marketing Pharmaceuticals (OTC: CWNM [http://finance.yahoo.com/q?s=cwnm&ql=1 ]) announced today that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin....
Watch the video "Diabetes Drug Could Hold Promise For Lung Cancer Patients" Brett Smith for redOrbit.com - Your Universe Online Scientists have been enthusiastic about the potential use of widely available diabetes drugs to treat various types of cancer. A new study from The Salk Institute for Biological Studies and the David Geffen UCLA School of Medicine suggests that these metabolism-affecting drugs can decrease the size of lung tumors in mice and increase their chances for...
INGELHEIM, Germany, Jan. 7, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT-2) inhibitor being studied for treatment of patients with type 2 diabetes (T2D). In all four studies, the primary efficacy endpoint, defined as significant change in HbA1c from baseline compared to placebo, was met with...
redOrbit Staff & Wire Reports - Your Universe Online Metformin, the drug most frequently prescribed by doctors to treat Type 2 Diabetes, works differently than previously believed -- a discovery which could lead to new treatments that have fewer side effects. Lead researcher Dr. Morris J. Birnbaum, a professor at the University of Pennsylvania's Institute for Diabetes, Obesity, and Metabolism (IDOM), and an international team of scientists have discovered that, in mice, metformin...
RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. The kidneys of people with type 2...
Lee Rannals for redOrbit.com – Your Universe Online A common diabetes medication could help in preventing or treating ovarian cancer, according to research published in the journal CANCER. The study found that ovarian cancer patients who took the drug tended to live longer than those patients who did not take it. Previous research showed that metformin, which originated from the French Lilac plant, might have anticancer properties. In the new study, the researchers analyzed...
